Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ).
Shandong Xinhua Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has received a Drug Registration Certificate for its Ivabradine Hydrochloride Tablets from the National Medical Products Administration. This approval marks a significant milestone for the company, enhancing its product portfolio and potentially strengthening its position in the pharmaceutical industry by expanding its offerings in the prescription drug market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and distribution of prescription drugs. The company is involved in the development of various pharmaceutical products, with a market focus on both domestic and international markets.
Average Trading Volume: 4,889,496
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.26B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.